Biotech Stocks
Recent market-moving SEC filings and news across biotech companies, ranked by Wiseek's 1–10 importance score.
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a biotech company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
Related Healthcare industries
Medical Device StocksPharmaceutical StocksHealth Tech StocksDiagnostics & Research StocksMedical Instrument StocksHealthcare Facility Stocks
See the full Healthcare sector feed.
$50M Private Placement Priced at $33.21, Led by Cormorant
GridAI Registers 9.9M Shares for Resale, Including New $8.5M July Placement, Extending Cash Runway to 18 Months
Inventiva wraps up EIB warrant restructuring with 15.7M new warrants at a €0.01 strike
CollPlant Registers 31M Shares for Resale from $2.6M Private Placement
Inventiva Finalizes EIB Warrant Restructuring, Eliminates Anti-Dilution Overhang
Bio-Techne Lays Out Equity Award Mechanics for Merck KGaA Buyout
Biodexa Sets July 29 Vote on 1-for-10,000 Reverse Split and £25M Share Authorization
Mitesco Registers 106.5M Shares for Resale — Potential Dilution Exceeds 80%
Nurix Q2 Loss Widens to $89.5M; Cash at $443.5M, Pro-Forma $1.14B with Roche Deal
CervoMed wraps up enrollment in Phase 2a neflamapimod trial for frontotemporal dementia
Nurix Q2 2026: $443.5M Cash, $89.5M Net Loss; Bexobrutideg Data and Roche Deal Progress
Pulmatrix Files S-4 for Reverse Merger with Eos SENOLYTIX, Issuing 75M Shares and Proposing Reverse Split
60 Degrees Pharma Submits Statistical Plan for Tafenoquine Trial, Eyes Priority Review Voucher
TuHURA Seeks Stockholder Nod for $5M Fee Share Issuance to Major Holder Affiliate
ImmuCell Q2 Sales Jump 12% to $7.2M, Six-Month Revenue Up 21%
Shareholders greenlight a 2-million-share plan expansion and warrant issuance, deepening dilution for Traws Pharma
Nurix Posts $443.5M Cash, Roche Deal Closing Nears with $700M Upfront
Eplontersen Stumbles in Phase 3 ATTR-CM Trial, Setting Ionis Up for a Sharp Stock Decline
MetaVia's Obesity Drug DA-1726 Completes Dose Titration in Phase 1, Topline Data on Track for Q4 2026
FDA Clears First-Ever IND for Peeling Skin Syndrome, Quoin to Start Phase 2
FDA Clears Fate's FT839 Dual-Targeting CAR T for Autoimmune Trial
FB102 Hits 29.6% Vitiligo Improvement in Phase 1b, Paving Path to Pivotal Trials
FB102 Hits Primary Endpoint in Phase 1b Vitiligo Trial, Setting Stage for Forte Surge
IN8bio's DeltEx DRI Doubles Progression-Free Survival in Glioblastoma, Published in JCO
Virax Biolabs Locks In Exclusive Fosun Diagnostics Supply Deal Across Six Southeast Asian Markets
CervoMed Completes Enrollment in Phase 2 Neflamapimod Study for Rare Dementia
Virax Biolabs Inks Multi-Country Supply Deal with Fosun Diagnostics for ImmuneSelect
Moderna Wins EU Contract for RSV Vaccine, Up to 24M Doses
New Imaging Data Show XPro's Early Brain Microstructure Effects in Alzheimer's
Kyverna Extends $15M Loan Draw Window, Securing Future Capital Access
Preliminary Phase III Data Shows 70-80% Recurrence Reduction for Greenwich LifeSciences' GP2
AstraZeneca-Ionis Heart Drug Wainua Fails Late-Stage Trial Main Goal
Radoff-JEC Group Slams Seer Board for Hypocrisy on CEO's Buyout Bid, Urges Vote for Independent Directors
Catalyst Pharma Shareholders Approve $4.1 Billion Acquisition by Angelini Pharma
Oncolytics Biotech Changes Auditor to Baker Tilly Amidst Corporate Restructuring
Akari Therapeutics Amends S-3, Details Warrants for Resale at Deep Discount
Q1 Loss Widens, Raises $1.2M Post-Quarter via SEPA Amid Strategic Pivot
Tarsus Acquires iRenix Medical for $75M Upfront to Expand Eye Care Pipeline with Late-Stage IRX-101
GSK Ends Alector Progranulin Pact After Drug Failures; Alector Repays $10.4M Loan
Forum Markets Discloses Massive Executive Compensation Amidst Deep Losses and High Potential Dilution